BridgeMD
“Pilot, open, non-comparative study to evaluate the safety and efficacy of Factor-Rich Plasma Intraovarian Growth in Patients with Low Reserve Ovarian”
EU CTIS ID: 2024-514444-87-00
What this study is testing
Evaluate the change in the number of oocytes retrieved between the in vitro fertilization (IVF) cycle prior to intraovarian PRGF administration and the cycle following the PRGF administration
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Women of group 3 and 4 of the POSEIDON classification for low reserve: POSEIDON 3: patients ˂ 35 years of age with diminished ovarian reserve (AMH <1.2 ng/ml, AFC <5). POSEIDON 4: patients ≥ 35 years of age with diminished ovarian reserve (AMH <1.2 ng/ml, AFC <5).
- Patients with at least one ovary.
- Infertility for at least one year
- Forecast of safe ovarian access on the day of puncture.
- Patients who agree to participate and give their written consent
You likely can't join if
- Patients with diagnosis of clinical ovarian insufficiency
- Patients affected by neoplastic disease
- Infertility with severe male factor
- Pregnant patients
- Current or previous IgA deficiency
- Ovarian failure secondary to identify genetic causes
See the full eligibility criteria
- Women of group 3 and 4 of the POSEIDON classification for low reserve: POSEIDON 3: patients ˂ 35 years of age with diminished ovarian reserve (AMH <1.2 ng/ml, AFC <5). POSEIDON 4: patients ≥ 35 years of age with diminished ovarian reserve (AMH <1.2 ng/ml, AFC <5).
- Patients with at least one ovary.
- Infertility for at least one year
- Forecast of safe ovarian access on the day of puncture.
- Patients who agree to participate and give their written consent
- Patients with diagnosis of clinical ovarian insufficiency
- Patients affected by neoplastic disease
- Infertility with severe male factor
- Pregnant patients
- Current or previous IgA deficiency
- Ovarian failure secondary to identify genetic causes
- Presence of pelvic adhesions after abdominal surgery
- Chronic use of aspirin, NSAIDs or anticoagulants
- Patients with psychiatric disorder precluding participation in the study (including abuse or dependence on psychoactive substances
- Obesity (BMI ≥ 30)
- Current cigarettes smoking (≥ 15 cigarettes per day)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.